Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MANISH A SHAH

Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology

NPI
1750473922
CMS profile
306260
Location
NEW YORK, NY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$41,584.99

62 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

By paying entity

PY2025 · entire year · sorted by reported total

Page 2 of 2; records 51–62 of 62 matching records. This page contains 12 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MANISH A SHAH

NPI 1750473922 · CMS profile ID 306260

Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology

NEW YORK, NY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–62 of 62 matching records. This page contains 12 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1750473922?year=2025&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MANISH A SHAH, NPI 1750473922, CMS profile ID 306260. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–62 of 62 matching records. This page contains 12 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1750473922?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). MANISH A SHAH, NPI 1750473922, CMS profile ID 306260. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–62 of 62 matching records. This page contains 12 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1750473922?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
MANISH A SHAH, NPI 1750473922, CMS profile ID 306260, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–62 of 62 matching records. This page contains 12 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1750473922?year=2025&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

62 matching records · $41,584.99 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 62 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–62 of 62.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
AstraZeneca Pharmaceuticals LP $24.5803/15/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1207256532 CMS
Novartis Pharmaceuticals Corporation $26.6203/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200567717 CMS
AstraZeneca Pharmaceuticals LP $16.0903/04/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206487536 CMS
Takeda Pharmaceuticals U.S.A., Inc. $125.0002/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1223941773 CMS
Merck Sharp & Dohme LLC $750.0002/17/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1238005400 CMS
Takeda Pharmaceuticals U.S.A., Inc. $2,415.0002/07/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1223786839 CMS
Immunocore Limited $30.0002/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1235824846 CMS
AstraZeneca Pharmaceuticals LP $24.7001/30/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1207208188 CMS
AstraZeneca Pharmaceuticals LP $74.0001/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206309382 CMS
Astellas Pharma US Inc $153.8501/23/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238725416 CMS
Merck Sharp & Dohme LLC $2,440.0001/15/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1238001480 CMS
Novartis Pharmaceuticals Corporation $28.4001/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200567713 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $80,721.07 58
PY2020 $42,923.04 23
PY2021 $50,545.15 24
PY2022 $12,806.62 4
PY2023 $23,966.13 24
PY2024 $54,215.83 41
PY2025 $41,584.99 62

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $866,414.51 60
PY2024 Principal investigator $1,282,556.58 23
PY2023 Principal investigator $830,705.37 14
PY2022 Recipient $1,015.68 1
PY2022 Principal investigator $511,621.28 46
PY2021 Principal investigator $1,870,563.03 22
PY2020 Recipient $1,412.59 2
PY2020 Principal investigator $1,886,859.76 81
PY2019 Principal investigator $1,530,967.29 93

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

60 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme LLC $161,563.19 12/31/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Randomized, Double-blind, Placebo-controlled Phase 3 Trial of Pembrolizumab MK-3475 Versus Placebo in Participants with Esophageal Carcinoma Receiving Concurrent Definitive Chemoradiotherapy KEYNOTE 975 No dispute reported 06/30/2026 1232927903
Principal investigator 1 Merck Sharp & Dohme LLC $166,551.68 12/31/2025 Non-covered Recipient Entity
Weill Cornell Medical College, NewYork Hospital
STUDY NAME#Phase II study of Suratadenoturev OBP-301 in combination with pembrolizumab in immunotherapy refractory esophagogastric adenocarcinoma No dispute reported 06/30/2026 1232935691
Principal investigator 1 Merck Sharp & Dohme LLC $21,246.06 12/31/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 3, Randomized Study to Evaluate the Efficacy and Safety of Pembrolizumab MK-3475 Lenvatinib E7080,MK-7902 Chemotherapy Compared with Standard of Care as First-line Intervention in Participants with Metastatic Esophageal Carcinoma No dispute reported 06/30/2026 1232938712
Principal investigator 1 Merck Sharp & Dohme LLC $140,126.46 12/15/2025 Non-covered Recipient Entity
WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY JOAN AND SANFORD I
Phase II study of Telomelysin OBP-301 in combination with pembrolizumab No dispute reported 06/30/2026 1232935689
Principal investigator 1 Merck Sharp & Dohme LLC $149,878.35 11/19/2025 Non-covered Recipient Entity
Weill Medical College of Cornell University
Multicenter, Randomized Phase II study evaluating Pembrolizumab in combination with chemotherapy and chemoradiation in locally advanced esophageal adenocarcinoma No dispute reported 06/30/2026 1232931838
Principal investigator 1 Astellas Pharma Global Development $10,200.00 11/05/2025 Non-covered Recipient Entity
WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY
A Phase 2 Study of Zolbetuximab (IMAB362) as Monotherapy or in Combination with mFOLFOX6 in Subjects with Metastatic or Locally Advanced Unresectable Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma whose Tumors Have High or Intermediate Claudin No dispute reported 06/30/2026 1234188077
Principal investigator 1 Astellas Pharma Global Development $3,725.00 11/05/2025 Non-covered Recipient Entity
WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY
A Phase 2 Study of Zolbetuximab (IMAB362) as Monotherapy or in Combination with mFOLFOX6 in Subjects with Metastatic or Locally Advanced Unresectable Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma whose Tumors Have High or Intermediate Claudin No dispute reported 06/30/2026 1234188079
Principal investigator 1 Astellas Pharma Global Development $3,780.00 11/05/2025 Non-covered Recipient Entity
WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY
A Phase 2 Study of Zolbetuximab (IMAB362) as Monotherapy or in Combination with mFOLFOX6 in Subjects with Metastatic or Locally Advanced Unresectable Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma whose Tumors Have High or Intermediate Claudin No dispute reported 06/30/2026 1234188081
Principal investigator 1 Astellas Pharma Global Development $2,025.00 11/05/2025 Non-covered Recipient Entity
WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY
A Phase 2 Study of Zolbetuximab (IMAB362) as Monotherapy or in Combination with mFOLFOX6 in Subjects with Metastatic or Locally Advanced Unresectable Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma whose Tumors Have High or Intermediate Claudin No dispute reported 06/30/2026 1234188083
Principal investigator 1 Astellas Pharma Global Development $3,000.00 11/05/2025 Non-covered Recipient Entity
WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY
A Phase 2 Study of Zolbetuximab (IMAB362) as Monotherapy or in Combination with mFOLFOX6 in Subjects with Metastatic or Locally Advanced Unresectable Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma whose Tumors Have High or Intermediate Claudin No dispute reported 06/30/2026 1234188085
Principal investigator 1 Astellas Pharma Global Development $3,725.00 11/05/2025 Non-covered Recipient Entity
WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY
A Phase 2 Study of Zolbetuximab (IMAB362) as Monotherapy or in Combination with mFOLFOX6 in Subjects with Metastatic or Locally Advanced Unresectable Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma whose Tumors Have High or Intermediate Claudin No dispute reported 06/30/2026 1234188087
Principal investigator 1 Astellas Pharma Global Development $3,000.00 11/05/2025 Non-covered Recipient Entity
WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY
A Phase 2 Study of Zolbetuximab (IMAB362) as Monotherapy or in Combination with mFOLFOX6 in Subjects with Metastatic or Locally Advanced Unresectable Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma whose Tumors Have High or Intermediate Claudin No dispute reported 06/30/2026 1234188089
Principal investigator 1 Astellas Pharma Global Development $250.00 11/05/2025 Non-covered Recipient Entity
WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY
A Phase 2 Study of Zolbetuximab (IMAB362) as Monotherapy or in Combination with mFOLFOX6 in Subjects with Metastatic or Locally Advanced Unresectable Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma whose Tumors Have High or Intermediate Claudin No dispute reported 06/30/2026 1234188091
Principal investigator 1 Astellas Pharma Global Development $1,000.00 11/05/2025 Non-covered Recipient Entity
WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY
A Phase 2 Study of Zolbetuximab (IMAB362) as Monotherapy or in Combination with mFOLFOX6 in Subjects with Metastatic or Locally Advanced Unresectable Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma whose Tumors Have High or Intermediate Claudin No dispute reported 06/30/2026 1234188093
Principal investigator 1 Astellas Pharma Global Development $1,891.00 11/05/2025 Non-covered Recipient Entity
WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY
A Phase 2 Study of Zolbetuximab (IMAB362) as Monotherapy or in Combination with mFOLFOX6 in Subjects with Metastatic or Locally Advanced Unresectable Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma whose Tumors Have High or Intermediate Claudin No dispute reported 06/30/2026 1234188095
Principal investigator 1 Astellas Pharma Global Development $3,500.00 11/05/2025 Non-covered Recipient Entity
WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY
A Phase 2 Study of Zolbetuximab (IMAB362) as Monotherapy or in Combination with mFOLFOX6 in Subjects with Metastatic or Locally Advanced Unresectable Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma whose Tumors Have High or Intermediate Claudin No dispute reported 06/30/2026 1234188097
Principal investigator 1 Astellas Pharma Global Development $2,000.00 11/05/2025 Non-covered Recipient Entity
WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY
A Phase 2 Study of Zolbetuximab (IMAB362) as Monotherapy or in Combination with mFOLFOX6 in Subjects with Metastatic or Locally Advanced Unresectable Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma whose Tumors Have High or Intermediate Claudin No dispute reported 06/30/2026 1234188099
Principal investigator 1 Astellas Pharma Global Development $1,888.00 11/05/2025 Non-covered Recipient Entity
WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY
A Phase 2 Study of Zolbetuximab (IMAB362) as Monotherapy or in Combination with mFOLFOX6 in Subjects with Metastatic or Locally Advanced Unresectable Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma whose Tumors Have High or Intermediate Claudin No dispute reported 06/30/2026 1234188101
Principal investigator 1 Astellas Pharma Global Development $1,824.00 11/05/2025 Non-covered Recipient Entity
WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY
A Phase 2 Study of Zolbetuximab (IMAB362) as Monotherapy or in Combination with mFOLFOX6 in Subjects with Metastatic or Locally Advanced Unresectable Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma whose Tumors Have High or Intermediate Claudin No dispute reported 06/30/2026 1234188103
Principal investigator 1 AstraZeneca Pharmaceuticals LP $51,125.00 09/30/2025 Non-covered Recipient Entity
WEILL CORNELL MEDICAL COLLEGE
a randomized,phase third study of rilvegostomig in combination with fluoropyrimidine and trastuzumab deruxtecan versus trastuzumab,chemotherapy,and pembrolizumab for the first line treatment of positive gastric cancer No dispute reported 06/30/2026 1185541136
Principal investigator 1 Merck Sharp & Dohme LLC $33,210.24 08/31/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 3, Randomized Study to Evaluate the Efficacy and Safety of Pembrolizumab MK-3475 Lenvatinib E7080,MK-7902 Chemotherapy Compared with Standard of Care as First-line Intervention in Participants with Metastatic Esophageal Carcinoma No dispute reported 06/30/2026 1232938714
Principal investigator 1 Astellas Pharma Global Development $1,761.75 07/28/2025 Non-covered Recipient Entity
WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY
A Phase 2 Study of Zolbetuximab (IMAB362) as Monotherapy or in Combination with mFOLFOX6 in Subjects with Metastatic or Locally Advanced Unresectable Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma whose Tumors Have High or Intermediate Claudin No dispute reported 06/30/2026 1234188005
Principal investigator 1 Astellas Pharma Global Development $1,548.00 07/28/2025 Non-covered Recipient Entity
WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY
A Phase 2 Study of Zolbetuximab (IMAB362) as Monotherapy or in Combination with mFOLFOX6 in Subjects with Metastatic or Locally Advanced Unresectable Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma whose Tumors Have High or Intermediate Claudin No dispute reported 06/30/2026 1234188007
Principal investigator 1 Astellas Pharma Global Development $5,150.00 07/28/2025 Non-covered Recipient Entity
WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY
A Phase 2 Study of Zolbetuximab (IMAB362) as Monotherapy or in Combination with mFOLFOX6 in Subjects with Metastatic or Locally Advanced Unresectable Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma whose Tumors Have High or Intermediate Claudin No dispute reported 06/30/2026 1234188009
Principal investigator 1 Astellas Pharma Global Development $1,548.00 07/28/2025 Non-covered Recipient Entity
WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY
A Phase 2 Study of Zolbetuximab (IMAB362) as Monotherapy or in Combination with mFOLFOX6 in Subjects with Metastatic or Locally Advanced Unresectable Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma whose Tumors Have High or Intermediate Claudin No dispute reported 06/30/2026 1234188011
Principal investigator 1 Astellas Pharma Global Development $1,548.00 07/28/2025 Non-covered Recipient Entity
WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY
A Phase 2 Study of Zolbetuximab (IMAB362) as Monotherapy or in Combination with mFOLFOX6 in Subjects with Metastatic or Locally Advanced Unresectable Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma whose Tumors Have High or Intermediate Claudin No dispute reported 06/30/2026 1234188013
Principal investigator 1 Astellas Pharma Global Development $3,456.00 07/28/2025 Non-covered Recipient Entity
WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY
A Phase 2 Study of Zolbetuximab (IMAB362) as Monotherapy or in Combination with mFOLFOX6 in Subjects with Metastatic or Locally Advanced Unresectable Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma whose Tumors Have High or Intermediate Claudin No dispute reported 06/30/2026 1234188015
Principal investigator 1 Astellas Pharma Global Development $1,548.00 07/28/2025 Non-covered Recipient Entity
WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY
A Phase 2 Study of Zolbetuximab (IMAB362) as Monotherapy or in Combination with mFOLFOX6 in Subjects with Metastatic or Locally Advanced Unresectable Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma whose Tumors Have High or Intermediate Claudin No dispute reported 06/30/2026 1234188017
Principal investigator 1 Astellas Pharma Global Development $3,456.00 07/28/2025 Non-covered Recipient Entity
WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY
A Phase 2 Study of Zolbetuximab (IMAB362) as Monotherapy or in Combination with mFOLFOX6 in Subjects with Metastatic or Locally Advanced Unresectable Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma whose Tumors Have High or Intermediate Claudin No dispute reported 06/30/2026 1234188019
Principal investigator 1 Astellas Pharma Global Development $2,328.75 07/28/2025 Non-covered Recipient Entity
WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY
A Phase 2 Study of Zolbetuximab (IMAB362) as Monotherapy or in Combination with mFOLFOX6 in Subjects with Metastatic or Locally Advanced Unresectable Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma whose Tumors Have High or Intermediate Claudin No dispute reported 06/30/2026 1234188021
Principal investigator 1 Astellas Pharma Global Development $810.00 07/28/2025 Non-covered Recipient Entity
WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY
A Phase 2 Study of Zolbetuximab (IMAB362) as Monotherapy or in Combination with mFOLFOX6 in Subjects with Metastatic or Locally Advanced Unresectable Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma whose Tumors Have High or Intermediate Claudin No dispute reported 06/30/2026 1234188023
Principal investigator 1 Astellas Pharma Global Development $2,328.75 07/28/2025 Non-covered Recipient Entity
WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY
A Phase 2 Study of Zolbetuximab (IMAB362) as Monotherapy or in Combination with mFOLFOX6 in Subjects with Metastatic or Locally Advanced Unresectable Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma whose Tumors Have High or Intermediate Claudin No dispute reported 06/30/2026 1234188025
Principal investigator 1 Astellas Pharma Global Development $5,150.00 07/28/2025 Non-covered Recipient Entity
WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY
A Phase 2 Study of Zolbetuximab (IMAB362) as Monotherapy or in Combination with mFOLFOX6 in Subjects with Metastatic or Locally Advanced Unresectable Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma whose Tumors Have High or Intermediate Claudin No dispute reported 06/30/2026 1234188027
Principal investigator 1 Astellas Pharma Global Development $1,548.00 07/28/2025 Non-covered Recipient Entity
WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY
A Phase 2 Study of Zolbetuximab (IMAB362) as Monotherapy or in Combination with mFOLFOX6 in Subjects with Metastatic or Locally Advanced Unresectable Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma whose Tumors Have High or Intermediate Claudin No dispute reported 06/30/2026 1234188029
Principal investigator 1 Astellas Pharma Global Development $3,456.00 07/28/2025 Non-covered Recipient Entity
WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY
A Phase 2 Study of Zolbetuximab (IMAB362) as Monotherapy or in Combination with mFOLFOX6 in Subjects with Metastatic or Locally Advanced Unresectable Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma whose Tumors Have High or Intermediate Claudin No dispute reported 06/30/2026 1234188031
Principal investigator 1 Astellas Pharma Global Development $810.00 07/28/2025 Non-covered Recipient Entity
WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY
A Phase 2 Study of Zolbetuximab (IMAB362) as Monotherapy or in Combination with mFOLFOX6 in Subjects with Metastatic or Locally Advanced Unresectable Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma whose Tumors Have High or Intermediate Claudin No dispute reported 06/30/2026 1234188033
Principal investigator 1 Astellas Pharma Global Development $1,548.00 07/28/2025 Non-covered Recipient Entity
WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY
A Phase 2 Study of Zolbetuximab (IMAB362) as Monotherapy or in Combination with mFOLFOX6 in Subjects with Metastatic or Locally Advanced Unresectable Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma whose Tumors Have High or Intermediate Claudin No dispute reported 06/30/2026 1234188035
Principal investigator 1 Astellas Pharma Global Development $1,548.00 07/28/2025 Non-covered Recipient Entity
WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY
A Phase 2 Study of Zolbetuximab (IMAB362) as Monotherapy or in Combination with mFOLFOX6 in Subjects with Metastatic or Locally Advanced Unresectable Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma whose Tumors Have High or Intermediate Claudin No dispute reported 06/30/2026 1234188037
Principal investigator 1 Astellas Pharma Global Development $1,548.00 07/28/2025 Non-covered Recipient Entity
WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY
A Phase 2 Study of Zolbetuximab (IMAB362) as Monotherapy or in Combination with mFOLFOX6 in Subjects with Metastatic or Locally Advanced Unresectable Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma whose Tumors Have High or Intermediate Claudin No dispute reported 06/30/2026 1234188039
Principal investigator 1 Astellas Pharma Global Development $2,631.00 07/28/2025 Non-covered Recipient Entity
WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY
A Phase 2 Study of Zolbetuximab (IMAB362) as Monotherapy or in Combination with mFOLFOX6 in Subjects with Metastatic or Locally Advanced Unresectable Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma whose Tumors Have High or Intermediate Claudin No dispute reported 06/30/2026 1234188041
Principal investigator 1 Astellas Pharma Global Development $992.25 07/28/2025 Non-covered Recipient Entity
WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY
A Phase 2 Study of Zolbetuximab (IMAB362) as Monotherapy or in Combination with mFOLFOX6 in Subjects with Metastatic or Locally Advanced Unresectable Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma whose Tumors Have High or Intermediate Claudin No dispute reported 06/30/2026 1234188043
Principal investigator 1 Astellas Pharma Global Development $1,417.50 07/28/2025 Non-covered Recipient Entity
WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY
A Phase 2 Study of Zolbetuximab (IMAB362) as Monotherapy or in Combination with mFOLFOX6 in Subjects with Metastatic or Locally Advanced Unresectable Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma whose Tumors Have High or Intermediate Claudin No dispute reported 06/30/2026 1234188045
Principal investigator 1 Astellas Pharma Global Development $2,565.00 07/28/2025 Non-covered Recipient Entity
WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY
A Phase 2 Study of Zolbetuximab (IMAB362) as Monotherapy or in Combination with mFOLFOX6 in Subjects with Metastatic or Locally Advanced Unresectable Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma whose Tumors Have High or Intermediate Claudin No dispute reported 06/30/2026 1234188047
Principal investigator 1 Astellas Pharma Global Development $810.00 07/28/2025 Non-covered Recipient Entity
WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY
A Phase 2 Study of Zolbetuximab (IMAB362) as Monotherapy or in Combination with mFOLFOX6 in Subjects with Metastatic or Locally Advanced Unresectable Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma whose Tumors Have High or Intermediate Claudin No dispute reported 06/30/2026 1234188049
Principal investigator 1 Astellas Pharma Global Development $2,565.00 07/28/2025 Non-covered Recipient Entity
WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY
A Phase 2 Study of Zolbetuximab (IMAB362) as Monotherapy or in Combination with mFOLFOX6 in Subjects with Metastatic or Locally Advanced Unresectable Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma whose Tumors Have High or Intermediate Claudin No dispute reported 06/30/2026 1234188051
Principal investigator 1 Astellas Pharma Global Development $2,416.50 07/28/2025 Non-covered Recipient Entity
WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY
A Phase 2 Study of Zolbetuximab (IMAB362) as Monotherapy or in Combination with mFOLFOX6 in Subjects with Metastatic or Locally Advanced Unresectable Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma whose Tumors Have High or Intermediate Claudin No dispute reported 06/30/2026 1234188053
Principal investigator 1 Astellas Pharma Global Development $3,456.00 07/28/2025 Non-covered Recipient Entity
WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY
A Phase 2 Study of Zolbetuximab (IMAB362) as Monotherapy or in Combination with mFOLFOX6 in Subjects with Metastatic or Locally Advanced Unresectable Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma whose Tumors Have High or Intermediate Claudin No dispute reported 06/30/2026 1234188055
Principal investigator 1 Astellas Pharma Global Development $2,328.75 07/28/2025 Non-covered Recipient Entity
WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY
A Phase 2 Study of Zolbetuximab (IMAB362) as Monotherapy or in Combination with mFOLFOX6 in Subjects with Metastatic or Locally Advanced Unresectable Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma whose Tumors Have High or Intermediate Claudin No dispute reported 06/30/2026 1234188057
Principal investigator 1 Astellas Pharma Global Development $1,863.00 07/28/2025 Non-covered Recipient Entity
WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY
A Phase 2 Study of Zolbetuximab (IMAB362) as Monotherapy or in Combination with mFOLFOX6 in Subjects with Metastatic or Locally Advanced Unresectable Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma whose Tumors Have High or Intermediate Claudin No dispute reported 06/30/2026 1234188059
Principal investigator 1 Astellas Pharma Global Development $4,030.00 07/28/2025 Non-covered Recipient Entity
WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY
A Phase 2 Study of Zolbetuximab (IMAB362) as Monotherapy or in Combination with mFOLFOX6 in Subjects with Metastatic or Locally Advanced Unresectable Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma whose Tumors Have High or Intermediate Claudin No dispute reported 06/30/2026 1234188061
Principal investigator 1 Astellas Pharma Global Development $2,328.75 07/28/2025 Non-covered Recipient Entity
WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY
A Phase 2 Study of Zolbetuximab (IMAB362) as Monotherapy or in Combination with mFOLFOX6 in Subjects with Metastatic or Locally Advanced Unresectable Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma whose Tumors Have High or Intermediate Claudin No dispute reported 06/30/2026 1234188063
Principal investigator 1 Astellas Pharma Global Development $2,328.75 07/28/2025 Non-covered Recipient Entity
WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY
A Phase 2 Study of Zolbetuximab (IMAB362) as Monotherapy or in Combination with mFOLFOX6 in Subjects with Metastatic or Locally Advanced Unresectable Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma whose Tumors Have High or Intermediate Claudin No dispute reported 06/30/2026 1234188065
Principal investigator 1 Astellas Pharma Global Development $1,548.00 07/28/2025 Non-covered Recipient Entity
WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY
A Phase 2 Study of Zolbetuximab (IMAB362) as Monotherapy or in Combination with mFOLFOX6 in Subjects with Metastatic or Locally Advanced Unresectable Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma whose Tumors Have High or Intermediate Claudin No dispute reported 06/30/2026 1234188067
Principal investigator 1 Astellas Pharma Global Development $1,417.50 07/28/2025 Non-covered Recipient Entity
WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY
A Phase 2 Study of Zolbetuximab (IMAB362) as Monotherapy or in Combination with mFOLFOX6 in Subjects with Metastatic or Locally Advanced Unresectable Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma whose Tumors Have High or Intermediate Claudin No dispute reported 06/30/2026 1234188069
Principal investigator 1 Astellas Pharma Global Development $2,631.00 07/28/2025 Non-covered Recipient Entity
WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY
A Phase 2 Study of Zolbetuximab (IMAB362) as Monotherapy or in Combination with mFOLFOX6 in Subjects with Metastatic or Locally Advanced Unresectable Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma whose Tumors Have High or Intermediate Claudin No dispute reported 06/30/2026 1234188071
Principal investigator 1 Astellas Pharma Global Development $992.25 07/28/2025 Non-covered Recipient Entity
WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY
A Phase 2 Study of Zolbetuximab (IMAB362) as Monotherapy or in Combination with mFOLFOX6 in Subjects with Metastatic or Locally Advanced Unresectable Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma whose Tumors Have High or Intermediate Claudin No dispute reported 06/30/2026 1234188073
Principal investigator 1 Astellas Pharma Global Development $4,030.00 07/28/2025 Non-covered Recipient Entity
WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY
A Phase 2 Study of Zolbetuximab (IMAB362) as Monotherapy or in Combination with mFOLFOX6 in Subjects with Metastatic or Locally Advanced Unresectable Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma whose Tumors Have High or Intermediate Claudin No dispute reported 06/30/2026 1234188075
Principal investigator 1 Merck Sharp & Dohme LLC $12,957.03 05/07/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 3, Randomized Study to Evaluate the Efficacy and Safety of Pembrolizumab MK-3475 Lenvatinib E7080,MK-7902 Chemotherapy Compared with Standard of Care as First-line Intervention in Participants with Metastatic Esophageal Carcinoma No dispute reported 06/30/2026 1232938710
Principal investigator 1 Astellas Pharma Global Development $1,890.00 03/07/2025 Non-covered Recipient Entity
WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY
A Phase 3, Global, Multi-Center, Double-Blind, Randomized, Efficacy Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma No dispute reported 06/30/2026 1234188003
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $4,616.00 01/21/2025 Non-covered Recipient Entity
Weill Medical College Of Cornell University
Prospective Evaluation of Nivolumab in Adjuvant Esophageal Cancer/Gastroesophageal Junction Cancer: A Non-interventional Study No dispute reported 06/30/2026 1235991730